Therapeutic area intelligence for Familial Adenomatous Polyposis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Erlotinib →

TPST-1495 →

Recent signals(2)

ClinicalAugust 2, 2026

Study Reviews Endoscopy Reports Post-Erlotinib in Familial Adenomatous Polyposis

The study aims to assess disease progression in familial adenomatous polyposis patients after stopping erlotinib treatment.

ClinicalJuly 9, 2026

Phase II Trial of TPST-1495 in Familial Adenomatous Polyposis Patients

The NCI is conducting an open-label phase II trial to evaluate the efficacy of TPST-1495 in reducing polyps in FAP patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.